This report is primarily intended for the community of policymakers and researchers concerned about the rising risks of domestic, regional, and global infectious disease epidemics, and the collective failure to take the coordinated actions required to reduce such risks. These risks include the expec...ted health, economic, and societal costs that are borne by countries, regions, and even all nations in the case of pandemics (which are worldwide epidemics). These risks also include the consequences of increasing antimicrobial resistance (AMR) and its spread within regions and globally. A necessary first step is to monitor whether a broad range of stakeholders are acting to prevent outbreaks from becoming epidemics, whether their capacities to respond to epidemics are robust, and whether preparedness to respond to pandemics and limit the resulting economic and health damage is improving. Analyzing the adequacy of these efforts is vitally important for the decisions of policymakers to invest in the public health and disaster-risk management capacities. Early and effective control of disease outbreaks prevents substantial health and economic costs whether or not the disease can spread globally and become a pandemic.
more
Disaster Recovery Toolkit
The ‘Toolkit’ is targeted at practitioners responsible for implementing recovery programmes, their objective to provide a ‘how to’ guide on development, implementing and managing complex post-disaster recovery programmes.
Disaster Recovery Toolkit
Disaster Recovery Toolkit
In the aftermath of the April 2015 earthquake in Nepal, this paper looks at lessons drawn from previous comparable disasters and seeks to provide invaluable information and assistance to the operational agencies responding to the crisis.
Learning from the Pakistan Experience. A Manual for Post-Disaster Housing Program Managers
Document No. : FDA/SMC/SMD/GL-RAR/2013/01
5th revised edition.
This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition
The Zimbabwe National Pharmacovigilance Policy Handbook, 2nd Edition updates the November 2013 version to indicate the Zimbabwe National Pharmacovigilance (PV) Centre’s compliance with the WHO Pharmacovigilance Indicators Handbook 2015.